InnovAge Holding Corp. Signals Momentum Amid Rising Costs

Innovage Holding Corp. ((INNV)) has held its Q3 earnings call. Read on for the main highlights of the call.

InnovAge Holding Corp.’s latest earnings call struck a cautiously upbeat tone, highlighting solid revenue growth, stronger margins and healthier cash generation, even as GAAP losses swelled on litigation costs and wage inflation. Management emphasized that underlying operations are improving and argued the business is better positioned to weather looming reimbursement headwinds.

Revenue Growth Accelerates on Higher Rates and Volume

InnovAge reported Q3 FY2026 revenue of $251.9 million, up 15.5% year over year and 5.1% sequentially, fueled by higher capitation rates and growing member months. The company continues to benefit from both pricing and volume tailwinds as it expands its PACE footprint.

Full-Year Outlook Raised After Outperformance

On the back of strong quarterly results, management lifted full-year FY2026 revenue guidance to $950 million–$975 million and raised adjusted EBITDA expectations to $85 million–$90 million. The upgrade signals confidence that current momentum in utilization and cost control can be sustained through year-end.

Adjusted EBITDA and Margins Show Sharp Turnaround

Adjusted EBITDA surged to $30.5 million from $10.8 million a year ago, with the margin jumping to 12.1% from 4.9% and improving sequentially from 9.2%. This marked margin expansion underscores a more disciplined cost structure and improving operating leverage as volumes scale.

Center-Level Profitability Expands Meaningfully

Center-level contribution margin rose to $61 million, or 24.2% of revenue, versus $40.7 million and 18.7% a year earlier, a roughly 550 basis-point improvement. On a dollar basis, contribution margin climbed 15.5% from the prior quarter’s $52.8 million, showing consistent operational progress at the site level.

Participant Census and Member Months Trend Higher

InnovAge served about 8,050 participants across 20 centers as of March 31, 2026, with census up 6.9% year over year and 0.5% sequentially. Member months reached 24,060, rising 6.7% from a year earlier and 0.4% from the prior quarter, underscoring steady demand for the company’s PACE services.

Cash Generation and Balance Sheet Strength Improve

The company delivered $18.1 million of operating cash flow in the quarter, reinforcing that the business is converting earnings into cash. Liquidity remains solid with about $138.6 million in cash and short-term investments against $69.4 million of total debt, giving InnovAge flexibility to fund growth and absorb volatility.

Efficiency Gains Lower Care Costs Per Participant

Management highlighted lower cost per participant driven by reduced permanent nursing facility utilization and savings from the shift to in-house pharmacy services. Despite member growth, external provider costs rose only 5% year over year, reflecting productivity gains and tighter clinical and operational management.

Strategic Investments Target Technology and Growth

InnovAge is plowing some of its margin gains back into clinical staffing, technology and growth initiatives, including AI pilots for care coordination, scheduling and transportation. The company is also ramping sales and marketing and pursuing new centers in Florida plus M&A and partnership opportunities to extend its reach.

GAAP Net Loss Widens Despite Operational Progress

The firm posted a GAAP net loss of $29.9 million in Q3 FY2026, deeper than the $11.1 million loss a year earlier, translating to a loss of $0.22 per diluted share. The widening loss underscores that while underlying operations are improving, significant non-operating and overhead items still weigh on bottom-line profitability.

Litigation-Driven G&A Surge Inflates Overhead

Corporate general and administrative expenses jumped to $76.5 million, up 98.3% year over year and 187.6% sequentially, primarily due to higher litigation-related liabilities. This spike in G&A materially distorted reported earnings, creating a gap between adjusted metrics and GAAP results.

Rising Care Costs and Wage Inflation Pressure Margins

Cost of care excluding depreciation and amortization rose to $77.7 million, up 11.8% from last year and 3.7% sequentially, as wage rates and benefits climbed. Higher third-party fees tied to the in-house pharmacy transition and elevated fleet and transportation costs further added to operating expense pressure.

Reimbursement Headwinds Emerging in Medicaid and Medicare

Management flagged early signs of state Medicaid budget pressure and projected only modest Medicare rate growth of roughly 1.5%–2% in FY2027. Lower-than-historic Medicaid increases could constrain top-line growth in future years, making ongoing efficiency and cost discipline increasingly critical.

Sales and Marketing Spend Rises to Support Growth

Sales and marketing expenses increased to about $8.7 million, up 26.3% year over year and 8.2% sequentially, reflecting higher wage rates and stepped-up marketing. While the spending lifts near-term operating costs, InnovAge views it as necessary to drive sustained participant growth.

De Novo Centers Still a Drag but Strategic

De novo losses totaled $1.8 million in the quarter, mainly from the Orlando center, and are expected to reach $11.5 million–$13.5 million for FY2026. These early-stage losses are a headwind to current earnings but are framed as long-term investments to expand the company’s geographic footprint and future revenue base.

Guidance and Outlook Emphasize Growth with Caution

For FY2026, InnovAge now guides to revenue of $950 million–$975 million, adjusted EBITDA of $85 million–$90 million and an ending census of 7,900–8,100 participants, with member months of 92,900–95,700 and de novo losses of $11.5 million–$13.5 million. Management also flagged FY2027 assumptions of modest Medicare rate growth and potential Medicaid pressure, suggesting a more challenging reimbursement backdrop despite current momentum.

InnovAge’s call painted a picture of a business that is strengthening operationally and financially while still grappling with litigation costs, wage inflation and rate uncertainty. For investors, the story is one of improving core fundamentals, expanding margins and solid liquidity, tempered by GAAP losses and reimbursement risk that will require sustained execution to overcome.